Basilea Begins Phase 2a Expansion Trial Testing BAL101553 in Ovarian, Brain Cancers

Basilea Begins Phase 2a Expansion Trial Testing BAL101553 in Ovarian, Brain Cancers
Basilea Pharmaceutica has dosed its first patient in the expansion part of its Phase 1/2 trial (NCT02895360), which continues to explore the safety and effectiveness of BAL101553, an investigational tumor checkpoint controller, for the treatment of glioblastoma and ovarian cancer. The open-label Phase 2a expansion is designed to include up to 40 patients with either recurrent glioblastoma — the most aggressive form of brain cancer — or ovarian cancer that failed prior platinum-based chemotherapy. The study is being conducted across several centers in Switzerland. "The start of the Phase 2a expansion study marks a significant milestone towards establishing clinical proof-of-concept for our biomarker-driven development strategy with our novel tumor checkpoint controller BAL101553,” Marc Engelhardt, MD, Basilea's chief medical officer, said in a press release. Cells proliferate in a regulated way, using information about their own internal state and the environment to decide whether to proceed with cell division. If a cell is damaged or fails to meet the requisites to move through the next phase of division, the cycle is halted. This is achieved through a number of checkpoints. BAL101553 is a small molecule that activates a checkpoint responsible for assessing if the chromosomes are correctly displayed to be segregated into two daughter cells. By activating this checkpoint, t
Subscribe or to access all post and page content.